The Lancet Publishes Results From Pivotal Study Of Eisai's Halaven® In Patients With

[News]

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that results from a pivotal study with HALAVEN® (eribulin mesylate), a novel anticancer agent discovered and developed by the company, will be published in the medical journal The Lancet1)...

More... (http://www.medicalnewstoday.com/articles/218301.php)